Dermatology Advisor

Deucravacitinib Is Effective for PsO Following Inadequate Response to Apremilast

Deucravacitinib in patients with plaque psoriasis who did not have adequate response to apremilast is effective and ...
Nasdaq

Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla® (apremilast) in Pivotal Phase 3 Psoriasis Study

Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
Pharmabiz

Bristol Myers announces positive results from POETYK PSO-1 phase 3 study of deucravacitinib to treat severe psoriasis patients

Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...
Twinfinite

Games Like Phantasy Star Online 2 (PSO2) If You’re Looking for Something Similar

Although the setting is extremely different, the closest comparison to Phantasy Star Online 2 (aside from previous games of course) is probably Diablo. You’ll likely want to go for Diablo III, the ...
Monthly Prescribing Reference

FDA Approves Sotyktu for Moderate to Severe Plaque Psoriasis

The approval was based on data from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials in adults with moderate to severe plaque psoriasis. The Food and Drug Administration (FDA) has approved Sotyktu ™ ...
Pharmabiz

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis

Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...